Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease

Expert Review of Clinical Immunology

Volumn 6, Issue 1, 2010, Pages 47-54

  Guandalini, Stefano ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bifidobacterium; Crohns; IBD; Inflammatory bowel disease; Lactobacillus; Pouchitis; Probiotics; Saccharomyces; Ulcerative colitis; VSL 3

Indexed keywords

BALSALAZIDE; MESALAZINE; PREDNISOLONE; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; VSL3;

BIFIDOBACTERIACEAE; BIFIDOBACTERIUM LONGUM; CHRONIC DISEASE; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; ESCHERICHIA COLI NISSLE 1917; HUMAN; ILEITIS; LACTOBACILLUS; NONHUMAN; REMISSION; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; ANIMALS; CHILD; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; HUMANS; PROBIOTICS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77649150349     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.70     Document Type: Review

References (61)

1. Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat. Clin. Pract. 4(2), 78-91 (2007).
2. De Vries HS, Van Oijen MG, De Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in The Netherlands. Drug Saf. 31(12), 1135-1144 (2008).
3. Wong AP, Clark AL, Garnett EA et al. Use of complementary medicine in pediatric patients with inflammatory bowel disease: results from a multicenter survey. J. Pediatr. Gastroenterol. Nutr. 48(1), 55-60 (2009).
4. Lionetti P, Callegari Ml, Ferrari S et al. Enteral nutrition and microflora in pediatric Crohn's disease. JPEN J. Parenter. Enteral Nutr. 29(4 Suppl.), S173-S175; discussion S175-S178, S184-S178 (2005).
5. Cotter Pd, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat. Rev. 3(10), 777-788 (2005).
6. Lawton EM, Ross RP, Hill C, Cotter Pd. Two-peptide lantibiotics: a medical perspective. Mini Rev. Med. Chem. 7(12), 1236-1247 (2007).
7. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol. Rev. 28(4), 405-440 (2004).
8. Collado MC, Hernandez M, Sanz Y. Production of bacteriocin-like inhibitory compounds by human fecal bifidobacterium strains. J. Food Prot. 68(5), 1034-1040 (2005).
9. Makras L, Triantafyllou V, Fayol-Messaoudi D et al. Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Res. Microbiol. 157(3), 241-247 (2006).
10. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett. Appl. Microbiol. 45(4), 454-460 (2007). (Pubitemid 47493153)
11. Kadowaki N, Ho S, Antonenko S et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194(6), 863-869 (2001).
12. Drakes M, Blanchard T, Czinn S. Bacterial probiotic modulation of dendritic cells. Infect. Immun. 72(6), 3299-3309 (2004).
13. Smits HH, Engering A, Van Der Kleij D et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J. Allergy Clin. Immunol. 115(6), 1260-1267 (2005).
14. Mennigen R, Nolte K, Rijcken E et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am. J. Physiol. 296(5), G1140-G1149 (2009).
15. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and map kinasedependent mechanism. Am. J. Physiol. 294(4), G1060-G1069 (2008).
16. Moorthy G, Murali Mr, Devaraj SN. Lactobacilli facilitate maintenance of intestinal membrane integrity during Shigella dysenteriae 1 infection in rats. Nutrition 25(3), 350-358 (2009).
17. Ewaschuk JB, Diaz H, Meddings L et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am. J. Physiol. 295(5), G1025-G1034 (2008).
18. Putaala H, Salusjarvi T, Nordstrom M et al. Effect of four probiotic strains and Escherichia coli o157:H7 on tight junction integrity and cyclo-oxygenase expression. Res. Microbiol. 159(9-10), 692-698 (2008).
19. Lindfors K, Blomqvist T, Juuti-Uusitalo K et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin. Exp. Immunol. 152(3), 552-558 (2008).
20. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve zo-2 and PKCz redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 9(3), 804-816 (2007).
21. Montalto M, Maggiano N, Ricci R et al. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 69(4), 225-228 (2004).
22. Dalmasso G, Cottrez F, Imbert V et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131(6), 1812-1825 (2006).
23. Winkler P, Ghadimi D, Schrezenmeir J, Kraehenbuhl JP. Molecular and cellular basis of microflora-host interactions. J. Nutr. 137(3 Suppl. 2), 756S-772S (2007).
24. Li N, Russell WM, Douglas-Escobar M, Hauser N, Lopez M, Neu J. Live and heat-killed Lactobacillus rhamnosus GG (LGG): effects on pro and antiinflammatory cyto/chemokines in gastrostomy-fed infant rats. Pediatr. Res. 66(2), 203-207 (2009).
25. Matsumoto S, Hara T, Hori T et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of proinflammatory cytokines in lamina propria mononuclear cells. Clin. Exp. Immunol. 140(3), 417-426 (2005).
26. Sturm A, Rilling K, Baumgart DC et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via Toll-like receptor 2 signaling. Infect. Immun. 73(3), 1452-1465 (2005).
27. Llopis M, Antolin M, Carol M et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm. Bowel Dis. 15(2), 275-283 (2009).
28. Pronio A, Montesani C, Butteroni C et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis. 14(5), 662-668 (2008).
29. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm. Bowel Dis. 14(11), 1585-1596 (2008).
30. Chen Ll, Wang Xh, Cui Y et al. Therapeutic effects of four strains of probiotics on experimental colitis in mice. World J. Gastroenterol. 15(3), 321-327 (2009).
31. Soo I, Madsen Kl, Tejpar Q et al. Vsl#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can. J. Gastroenterol. 22(3), 237-242 (2008).
32. Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, Koltun WA. In vitro and in vivo effects of the probiotic Escherichia coli strain m-17: immunomodulation and attenuation of murine colitis. Br. J. Nutr. 100(3), 530-541 (2008).
33. Feighery LM, Smith P, O'mahony L, Fallon PG, Brayden DJ. Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease. Dig. Dis. Sci. 53(9), 2495-2506 (2008).
34. Nanda Kumar NS, Balamurugan R, Jayakanthan K, Pulimood A, Pugazhendhi S, Ramakrishna BS. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J. Gastroenterol. Hepatol. 23(12), 1834-1839 (2008).
35. Zoumpopoulou G, Foligne B, Christodoulou K, Grangette C, Pot B, Tsakalidou E. Lactobacillus fermentum ACA-DC 179 displays probiotic potential in vitro and protects against trinitrobenzene sulfonic acid (TNBS)- induced colitis and Salmonella infection in murine models. Int. J. Food Microbiol. 121(1), 18-26 (2008).
36. Wu X, Vallance BA, Boyer L et al. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am. J. Physiol. 294(1), G295-G306 (2008).
37. Chung YW, Choi JH, Oh TY, Eun CS, Han DS. Lactobacillus casei prevents the development of dextran sulphate sodiuminduced colitis in Toll-like receptor 4 mutant mice. Clin. Exp. Immunol. 151(1), 182-189 (2008).
38. Peran L, Camuesco D, Comalada M et al. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the Tnbs model of rat colitis. J. Appl. Microbiol. 103(4), 836-844 (2007). (Pubitemid 47493215)
39. Amit-Romach E, Uni Z, Reifen R. Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis. Dis. Colon Rectum 51(12), 1828-1836 (2008).
40. Fitzpatrick LR, Hertzog KL, Quatse AL, Koltun WA, Small JS, Vrana K. Effects of the probiotic formulation vsl#3 on colitis in weanling rats. J. Pediatr. Gastroenterol. Nutr. 44(5), 561-570 (2007).
41. Lee HS, Han SY, Bae EA et al. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int. Immunopharmacol. 8(4), 574-580 (2008).
42. Peran L, Sierra S, Comalada M et al. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br. J. Nutr. 97(1), 96-103 (2007). (Pubitemid 46662063)
43. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J. Clin. Gastroenterol. 25(4), 653-658 (1997).
44. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 4, 5 (2004).
45. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci. 45(7), 1462-1464 (2000).
46. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand. J. Gastroenterol. 43(7), 842-848 (2008).
47. Bousvaros A, Guandalini S, Baldassano RN et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. 11(9), 833-839 (2005).
48. Chermesh I, Tamir A, Reshef R et al. Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig. Dis. Sci. 52(2), 385-389 (2007).
49. Marteau P, Lemann M, Seksik P et al. Ineffectiveness of Lactobacillus johnsonii la1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled getaid trial. Gut 55(6), 842-847 (2006).
50. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51(3), 405-409 (2002).
51. Van Gossum A, Dewit O, Louis E et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, la1) on early endoscopic recurrence of Crohn's disease after ileo- caecal resection. Inflamm. Bowel Dis. 13(2), 135-142 (2007).
52. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol. Nutr. 31(4), 453-457 (2000).
53. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354(9179), 635-639 (1999).
54. Kato K, Mizuno S, Umesaki Y et al. Randomized placebo-controlled trial assessing the effect of bifidobacteriafermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. 20(10), 1133-1141 (2004).
55. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med. Sci. Monit. 10(11), PI126-PI131 (2004).
56. Furrie E, Macfarlane S, Kennedy A et al. Synbiotic therapy (Bifidobacterium longum/ synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54(2), 242-249 (2005).
57. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (vsl#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 104(2), 437-443 (2009).
58. Huynh HQ, Debruyn J, Guan L et al. Probiotic preparation vsl#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm. Bowel Dis. 15(5), 760-768 (2009).
59. Pakarinen MP, Natunen J, Ashorn M et al. Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics 123(5), 1377-1382 (2009).
60. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124(5), 1202-1209 (2003).
61. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebocontrolled trial. Gastroenterology 119(2), 305-309 (2000).